Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | GAA | P10253 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | HPGD | P15428 | 4/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 9/20 | 0.41 |
| ▸ | GLA | P06280 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | TOP2A | P11388 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 6/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21632144 | 0.87 | GAA (0.47) | KDM4EGAAALDH1A1HPGDTSHR | |
| SCHEMBL22790508 | 0.84 | TLR7 (0.48) | KDM4EGAAALDH1A1HPGDTSHR | |
| SCHEMBL20766797 | 0.81 | GAA (0.47) | KDM4EGAAALDH1A1HPGDGLA | |
| SCHEMBL28872741 | 0.80 | POLB (0.46) | TOP2APOLB | |
| SCHEMBL29378988 | 0.79 | GAA (0.46) | KDM4EGAAALDH1A1TLR7GLA | |
| SCHEMBL19469435 | 0.76 | EGFR (0.53) | ALDH1A1HPGDMAPTTOP2APOLB | |
| SCHEMBL24808190 | 0.76 | KDM4E (0.52) | KDM4EGAAALDH1A1HPGDTSHR | |
| SCHEMBL6722290 | 0.74 | TOP2A (0.52) | KDM4EGAAALDH1A1HPGDTSHR | |
| SCHEMBL24808465 | 0.73 | KDM4E (0.49) | KDM4EGAAALDH1A1HPGDTSHR | |
| SCHEMBL20801390 | 0.73 | TLR7 (0.51) | KDM4EGAAALDH1A1HPGDTLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210213010-A1 | TLR7/8 AGONISTS AND LIPOSOME COMPOSITIONS | DANMARKS TEKNISKE UNIVERSITET (DK) | 2021-07-15 | — | — | US | disclosed |
| EP-3827002-A1 | TLR7/8 AGONISTS AND LIPOSOME COMPOSITIONS | Torque Therapeutics, Inc. (US) | 2021-06-02 | — | — | EP | disclosed |
| WO-2020023680-A1 | TLR7/8 AGONISTS AND LIPOSOME COMPOSITIONS | TORQUE THERAPEUTICS, INC. (US) | 2020-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210213010-A1 | TLR7/8 AGONISTS AND LIPOSOME COMPOSITIONS | TLR7, TLR9, TLR8 | KDM4E 1036/4885GAA 1315/4885ALDH1A1 4407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.